Literature DB >> 33397287

Efficacy of intravenous lidocaine infusions for pain relief in children undergoing laparoscopic appendectomy: a randomized controlled trial.

Maciej Kaszyński1, Dorota Lewandowska2, Piotr Sawicki3, Piotr Wojcieszak3, Izabela Pągowska-Klimek3.   

Abstract

Intravenous lidocaine, a potent local anesthetic with analgesic and anti-inflammatory properties, has been shown to be an effective adjunct that reduces intra- and postoperative opioid consumption and facilitates pain management in adults. While it shows promise for use in the pediatric population, limited evidence is available.
OBJECTIVES: To determine if general anesthesia with intraoperative intravenous lidocaine infusion versus general anesthesia without intravenous lidocaine infusion in children undergoing laparoscopic appendectomy decreased opioid requirements intra- and postoperatively.
DESIGN: A single-center parallel single-masked randomized controlled study. A computer-generated blocked randomization list was used to allocate participants. The study was conducted between March 2019 and January 2020.
SETTING: Pediatric teaching hospital in Poland. PARTICIPANTS: Seventy-four patients aged between 18 months and 18 years undergoing laparoscopic appendectomy. Seventy-one patients fulfilled the study requirements. INTERVENTION: Intravenous lidocaine bolus of 1.5 mg/kg over 5 min before induction of anesthesia followed by lidocaine infusion at 1.5 mg/kg/h intraoperatively. The infusion was discontinued before the patients' transfer to the postanesthesia care unit (PACU). PRIMARY OUTCOME MEASURE: The primary outcome measure was total nalbuphine requirement in milligrams during the first 24 h after surgery. SECONDARY OUTCOME MEASURES: The secondary outcome measures were intraoperative fentanyl consumption, intraoperative sevoflurane consumption, time to the first rescue analgesic request, incidence of postoperative nausea and vomiting during the first 24 h after surgery, frequency of side effects of lidocaine.
RESULTS: Children (n = 74) aged 5-17 randomly allocated to receive intraoperative lidocaine infusion (n = 37) or no intervention (n = 37). Seventy-one were included in the analysis (35 in the study group and 36 in the control group). There was no difference in the cumulative dose of nalbuphine in the first 24 h after removal of the endotracheal tube between groups [median of 0.1061 (IQR: 0.0962-0.2222) mg/kg in the lidocaine group, compared to the control group median of 0.1325 (IQR: 0.0899-0.22020) mg/kg, p = 0.63]. Intraoperative fentanyl consumption was lower in the lidocaine group [median of 5.091 (IQR: 4.848-5.714) μg/kg] than in the control group [median of 5.969 (IQR: 5.000-6.748), p = 0.03]. Taking into account the additional doses administered based on clinical indications, the reduction in the requirement for fentanyl in the lidocaine group was even greater [median of 0.0 (IQR: 0.0-0.952) vs 0.99 (IQR: 0.0-1.809) μg/kg, p = 0.01]. No difference was observed in the sevoflurane consumption between the two groups [median of 32.5 ml (IQR 25.0-43.0) in the lidocaine group vs median of 35.0 ml (IQR: 23.5-46.0) in the control group, p = 0.56]. The time to first analgesic request in the lidocaine group was prolonged [median of 55 (IQR: 40-110) min in the lidocaine group vs median of 40.5 (IQR: 28-65) min in the control group, p = 0.05]. There was no difference in the frequency of PONV between the two groups (48.57% in the lidocaine group vs 61.11% in the control group, p = 0.29). No lidocaine related incidence of anaphylaxis, systemic toxicity, circulatory disturbances or neurological impairment was reported, during anesthesia or postoperative period.
CONCLUSIONS: Intraoperative systemic lidocaine administration reduced the intraoperative requirement for opioids in children undergoing laparoscopic appendectomy. This effect was time limited, and hence did not affect opioid consumption in the first 24 h following discontinuation of lidocaine infusion. TRIAL REGISTRATION: NCT03886896 .

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33397287      PMCID: PMC7784324          DOI: 10.1186/s12871-020-01218-0

Source DB:  PubMed          Journal:  BMC Anesthesiol        ISSN: 1471-2253            Impact factor:   2.217


  21 in total

1.  Effect of perioperative intravenous lidocaine infusion on postoperative recovery following laparoscopic Cholecystectomy-A randomized controlled trial.

Authors:  Xiaoli Song; Yanxia Sun; Xiaomei Zhang; Tianzuo Li; Binbin Yang
Journal:  Int J Surg       Date:  2017-07-10       Impact factor: 6.071

Review 2.  Perioperative Use of Intravenous Lidocaine.

Authors:  Lauren K Dunn; Marcel E Durieux
Journal:  Anesthesiology       Date:  2017-04       Impact factor: 7.892

3.  Fresh gas flow is not the only determinant of volatile agent consumption: a multi-centre study of low-flow anaesthesia.

Authors:  J F Coetzee; L J Stewart
Journal:  Br J Anaesth       Date:  2002-01       Impact factor: 9.166

4.  Intravenous lidocaine infusion facilitates acute rehabilitation after laparoscopic colectomy.

Authors:  Abdourahamane Kaba; Stanislas R Laurent; Bernard J Detroz; Daniel I Sessler; Marcel E Durieux; Maurice L Lamy; Jean L Joris
Journal:  Anesthesiology       Date:  2007-01       Impact factor: 7.892

5.  The effect of a bolus dose of intravenous lidocaine on the minimum alveolar concentration of sevoflurane: a prospective, randomized, double-blinded, placebo-controlled trial.

Authors:  Thomas Hamp; Mario Krammel; Ulrike Weber; Rainer Schmid; Alexandra Graf; Walter Plöchl
Journal:  Anesth Analg       Date:  2013-06-06       Impact factor: 5.108

Review 6.  Efficacy and safety of intravenous lidocaine for postoperative analgesia and recovery after surgery: a systematic review with trial sequential analysis.

Authors:  S Weibel; J Jokinen; N L Pace; A Schnabel; M W Hollmann; K Hahnenkamp; L H J Eberhart; D M Poepping; A Afshari; P Kranke
Journal:  Br J Anaesth       Date:  2016-06       Impact factor: 9.166

7.  Intraoperative infusion of lidocaine reduces postoperative fentanyl requirements in patients undergoing laparoscopic cholecystectomy.

Authors:  Severine Lauwick; Do Jun Kim; Giuliano Michelagnoli; Giovanni Mistraletti; Liane Feldman; Gerald Fried; Franco Carli
Journal:  Can J Anaesth       Date:  2008-11       Impact factor: 5.063

8.  Factors associated with intravenous lidocaine in pediatric patients undergoing laparoscopic appendectomy - a retrospective, single-centre experience.

Authors:  Christian P Both; Jörg Thomas; Philipp K Bühler; Achim Schmitz; Markus Weiss; Tobias Piegeler
Journal:  BMC Anesthesiol       Date:  2018-07-18       Impact factor: 2.217

9.  Analgesic effects of adding lidocaine to morphine pumps after orthopedic surgeries.

Authors:  Mahmoud Reza Alebouyeh; Farnad Imani; Poupak Rahimzadeh; Saeed Reza Entezary; Seyed Hamid Reza Faiz; Parisa Soraya
Journal:  J Res Med Sci       Date:  2014-02       Impact factor: 1.852

10.  Systemic Lidocaine Infusion for Post-Operative Analgesia in Children Undergoing Laparoscopic Inguinal Hernia Repair: A Randomized Double-Blind Controlled Trial.

Authors:  Hye-Mi Lee; Kwan-Woong Choi; Hyo-Jin Byon; Ji-Min Lee; Jeong-Rim Lee
Journal:  J Clin Med       Date:  2019-11-18       Impact factor: 4.241

View more
  3 in total

1.  Clinical Application of Artificial Intelligence: Auto-Discerning the Effectiveness of Lidocaine Concentration Levels in Osteosarcoma Femoral Tumor Segment Resection.

Authors:  Shuqin Ni; Xin Li; Xiuna Yi
Journal:  J Healthc Eng       Date:  2022-03-28       Impact factor: 2.682

2.  Impact of lidocaine on hemodynamic and respiratory parameters during laparoscopic appendectomy in children.

Authors:  Maciej Kaszyński; Barbara Stankiewicz; Krzysztof Jakub Pałko; Marek Darowski; Izabela Pągowska-Klimek
Journal:  Sci Rep       Date:  2022-08-18       Impact factor: 4.996

3.  Intravenous Lidocaine for Postoperative Analgesia in 90 patients After Total Knee Arthroplasty and Limb Fractures.

Authors:  Rajmonda Nallbani; Edmond Komoni; Fatos Sada; Ismet Q Jusufi; Antigona Hasani
Journal:  Med Sci Monit       Date:  2022-03-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.